Ocean Biomedical Stock Cash Flow From Operations
| OCEAW Stock | 0.03 0 9.61% |
Ocean Biomedical fundamentals help investors to digest information that contributes to Ocean Biomedical's financial success or failures. It also enables traders to predict the movement of Ocean Stock. The fundamental analysis module provides a way to measure Ocean Biomedical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Ocean Biomedical stock.
Ocean | Cash Flow From Operations |
Ocean Biomedical Company Cash Flow From Operations Analysis
Ocean Biomedical's Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current Ocean Biomedical Cash Flow From Operations | (9.43 M) |
Most of Ocean Biomedical's fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ocean Biomedical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Ocean Cash Flow From Operations Driver Correlations
Understanding the fundamental principles of building solid financial models for Ocean Biomedical is extremely important. It helps to project a fair market value of Ocean Stock properly, considering its historical fundamentals such as Cash Flow From Operations. Since Ocean Biomedical's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Ocean Biomedical's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Ocean Biomedical's interrelated accounts and indicators.
Click cells to compare fundamentals
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
| Competition |
In accordance with the recently published financial statements, Ocean Biomedical has (9.43 Million) in Cash Flow From Operations. This is 101.79% lower than that of the Biotechnology sector and 115.08% lower than that of the Health Care industry. The cash flow from operations for all United States stocks is 100.97% higher than that of the company.
Ocean Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ocean Biomedical's direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Ocean Biomedical could also be used in its relative valuation, which is a method of valuing Ocean Biomedical by comparing valuation metrics of similar companies.Ocean Biomedical is currently under evaluation in cash flow from operations category among its peers.
Ocean Fundamentals
| Number Of Shares Shorted | 44.5 K | ||||
| EBITDA | (957.74 K) | ||||
| Net Income | (114.47 M) | ||||
| Total Debt | 12.12 M | ||||
| Cash Flow From Operations | (9.43 M) | ||||
| Total Asset | 5.5 M | ||||
| Retained Earnings | (196.06 M) | ||||
| Working Capital | (27.9 M) | ||||
| Net Asset | 5.5 M |
About Ocean Biomedical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ocean Biomedical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ocean Biomedical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ocean Biomedical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Ocean Stock Analysis
When running Ocean Biomedical's price analysis, check to measure Ocean Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ocean Biomedical is operating at the current time. Most of Ocean Biomedical's value examination focuses on studying past and present price action to predict the probability of Ocean Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ocean Biomedical's price. Additionally, you may evaluate how the addition of Ocean Biomedical to your portfolios can decrease your overall portfolio volatility.